Stocks › IBRX
ImmunityBio, Inc.
IBRX·Nasdaq·
United States·USD
United States·USD$9.69
-0.69 (-6.65%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
IBRX
ImmunityBio, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
IBRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of IBRX by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Daniel S. GoldmanHouse · D · NY |
IBRXImmunityBio, Inc. · Stock |
Sale $1,001 - $15,000 |
Apr 17, 2023 | Mar 6, 2023 | Filing ↗ |
Whale Activity
Position changes in IBRX reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| DOLIVER ADVISORS, LP | 210.0K | $2.0M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by IBRX insiders, by quarter · Form 4
Recent Insider Transactions
116 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Simon Barry J.Director · Director | Sale | −25.0K | $10.75 | $269K | Oct 5, 2026 | Form 4 ↗ |
| Cohen CherylDirector · Director | Sale | −81.1K | $10.50 | $851K | Oct 2, 2026 | Form 4 ↗ |
| Cohen CherylDirector · Director | Sale | −131.2K | $9.50 | $1.2M | Jul 2, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector · Director | Sale | −159.5K | $9.02 | $1.4M | Jul 1, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector · Director | Sale | −1,000 | $9.00 | $9K | Jun 30, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector · Director | Sale | −95.7K | $9.01 | $862K | Jun 29, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −25.0K | $7.88 | $197K | Jun 24, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −23.0K | $7.18 | $165K | Jun 4, 2026 | Form 4 ↗ |
| CALIFORNIA CAPITAL EQUITY, LLC10% owner | Conversion | +4.6M | $5.43 | $25.0M | Mar 31, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −75.0K | $12.01 | $901K | Feb 24, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Sale | −25.0K | $10.00 | $250K | Feb 23, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +25.0K | $2.98 | $75K | Feb 23, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −165.0K | $10.25 | $1.7M | Feb 23, 2026 | Form 4 ↗ |
| Sachs David C.Chief Financial Officer | Tax withholding | −20.7K | $8.70 | $180K | Feb 22, 2026 | Form 4 ↗ |
| Sachs David C.Chief Financial Officer | Option exercise | +40.6K | $0.00 | $0 | Feb 22, 2026 | Form 4 ↗ |
| Adcock RichardCEO & President · Director | Tax withholding | −77.6K | $8.70 | $675K | Feb 22, 2026 | Form 4 ↗ |
| Adcock RichardCEO & President · Director | Option exercise | +152.4K | $0.00 | $0 | Feb 22, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Tax withholding | −6,026 | $8.70 | $52K | Feb 22, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Option exercise | +15.2K | $0.00 | $0 | Feb 22, 2026 | Form 4 ↗ |
| LAUER REGAN JChief Accounting Officer | Tax withholding | −1,673 | $8.70 | $15K | Feb 22, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding IBRX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 12.5M | $109.4M | 1.02% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 11.6M | $101.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 9.9M | $86.9M | 0.10% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 8.4M | $73.5M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 4.9M | $42.5M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.7M | $32.6M | 0.03% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 3.6M | $31.2M | 0.20% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 4.2M | $30.3M | 0.09% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 2.7M | $23.3M | 0.26% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 1.6M | $11.9M | 0.03% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list IBRX's shares (CUSIP 45256X103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Patrick Soon-ShiongSCHEDULE 13D/A · activist (13D) · 745.5M shares64.8%
Aug 6, 2026 · ↗ - California Capital Equity, LLCSCHEDULE 13D/A · activist (13D) · 106.5M shares10.0%
Aug 6, 2026 · ↗ - Nant Capital, LLCSCHEDULE 13D/A · activist (13D) · 339.5M shares29.6%
Aug 6, 2026 · ↗ - NantWorks, LLCSCHEDULE 13D/A · activist (13D) · 98.5M shares9.3%
Aug 6, 2026 · ↗ - MP 13 Ventures, LLCSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
Aug 6, 2026 · ↗ - Cambridge Equities, LPSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
Aug 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming immunitybio as client
- CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q2—
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q1$60K
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · HCR$60K
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · MED, HCR—
Filing ↗ - THE PETRIZZO GROUP, INC.IMMUNITYBIO, INC. · 2022 Q3 · MED, HCR$45K
Filing ↗
Government Contracts
Federal awards to ImmunityBio, Inc. · USAspending
No federal contract awards found for ImmunityBio, Inc..
U.S. Patents
Recent USPTO applications naming ImmunityBio, Inc.
No USPTO patent applications found for ImmunityBio, Inc..
Annual Financials
From IBRX's 10-K filings · XBRL
No annual XBRL figures on record for IBRX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in IBRX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About ImmunityBio, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001326110 ↗
Former namesNantKwest, Inc., Conkwest, Inc., ZelleRx Corp